By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Kingsfordweg 151

Amsterdam    1043 GR  The Netherlands
Phone: 31-0-20-4919602 Fax: 31-0-20-4919090



Start Up

Company News
Clinigen Group Acquires Oncology Support Therapy SAVENE® (Dexrazoxane) From SpePharm 3/31/2014 8:26:05 AM
SpePharm Sells Japanese Rights for Savene(R) to Kissei Pharmaceutical Co., Ltd. 9/1/2011 10:08:01 AM
BioAlliance Pharma Filed an Appeal to the French Supreme Court Contesting a Preliminary Procedural Decision on Jurisdiction in the Arbitration Against SpePharm and SpeBio 6/1/2011 12:53:45 PM
The Paris Court Of Appeals Rejects the Appeals Lodged by BioAlliance Pharma In A Case Against SpePharm and Spebio BV, And Orders Bioalliance Pharma to Refund in Total €500K Of Legal Costs to the Two Companies 5/31/2011 2:40:03 PM
SpePharm Announces the Acquisition of Savene(R) from TopoTarget A/S; 11 Million Euros New Round of Financing, and a Strategic Partnership with Paladin Labs Inc. (CC:PLB) 3/4/2010 6:55:53 AM
Access Pharmaceuticals (ACCP) Announces Commercial Launch of MuGard(TM) in Norway by SpePharm 7/27/2009 9:05:01 AM
Access Pharmaceuticals (ACCP) Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 6/30/2009 8:25:36 AM
Access Pharmaceuticals (ACCP) Announces the European Launch of MuGard(TM) by its European Partner, SpePharm 4/22/2009 8:50:33 AM
SpePharm Announces the European Launches of Two New Products: MuGard(R) and Xerotin(R) 4/20/2009 10:08:12 AM
SpePharm Announces a Claim in Excess of 35 Million Euros Against BioAlliance Pharma For Breaking up Their Joint-Venture 4/14/2009 6:57:48 AM